Search clinical trials for: SL TNX-102-A at 2.4 mg

Total 224 results

Tonix Pharmaceuticals, Inc.

Completed

Comparative Pharmacokinetics and Safety of TNX-102 SL Tablets and Cyclobenzaprine Oral Tablet in Healthy Adults

Healthy Adults

Canada
Tonix Pharmaceuticals, Inc.

Completed

Comparative Pharmacokinetics and Safety of 3 Different Formulations of TNX-102 2.8 mg SL Tablets and Cyclobenzaprine 5 mg Oral Tablet in Healthy Adults

Healthy Adults

Canada
AZ Sint-Jan AV

Completed

Catheter Ablation of All Inducible AT Post AF Ablation (INDUCATH)

Atrial Fibrillation | Atrial Tachycardia

France, Belgium, Germany, United Kingdom
Tonix Pharmaceuticals, Inc.

Completed

A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection (PREVAIL)

COVID-19 | Long COVID | Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection | Long Haul COVID

United States
Tonix Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions (AtEase)

PTSD

United States
Tonix Pharmaceuticals, Inc.

Completed

A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia (RESILIENT)

Fibromyalgia

United States
Tonix Pharmaceuticals, Inc.

Completed

Comparative Bioavailability of Sublingual TNX-102, Oral and Intravenous Cyclobenzaprine in Healthy Adults

Healthy Adults

Canada
Tonix Pharmaceuticals, Inc.

Completed

A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD (P306)

PTSD

United States
Tonix Pharmaceuticals, Inc.

Terminated

Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia (RE-AFFIRM)

Nervous System Diseases | Musculoskeletal Diseases | Rheumatic Diseases | Muscular Diseases | Neuromuscular Diseases | Fibromyalgia | Myofascial Pain Syndromes

United States
Tonix Pharmaceuticals, Inc.

Terminated

A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD (RECOVERY)

PTSD

United States
Tonix Pharmaceuticals, Inc.

Terminated

A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients

Primary Fibromyalgia

United States
Lundbeck Canada Inc.

Completed

Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia (BENDACT)

Chronic Lymphocytic Leukemia | Indolent Non-Hodgkin's Lymphoma

Canada
Aviragen Therapeutics

Completed

A Study to Compare the Oral Bioavailability of Single Doses of Three Vapendavir Drug Formulations in Healthy Volunteers

Healthy

United States
Nymox Corporation

Completed

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Prostate Cancer

United States
MacroGenics

Active, not recruiting

A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors (Tamarack)

Melanoma | Non-small Cell Lung Cancer | Small-cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Anal Cancer | Malignant Melanoma | Non-small Cell Carcinoma | Oral Squamous Cell Carcinoma | Small Cell Carcinoma | Laryngeal Squamous Cell Carcinoma | Carcinoma, Squamous Cell of Head and Neck | Castration-Resistant... and other conditions

Spain, Australia, United States, Korea, Republic of, France, United Kingdom, Italy, Belgium, Poland
OrthoTrophix, Inc

Completed

A Study Evaluating the Safety and Efficacy of a Second Course of TPX-100 in Subjects Who Previously Received TPX-100 for Patellar Osteoarthritis Involving Both Knees

Knee Osteoarthritis
Amgen

Completed

A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma

Advanced Renal Cell Carcinoma
Amgen

Completed

A Phase II Study to Treat Advanced Malignant Glioma

Advanced Malignant Glioma
Tonix Pharmaceuticals, Inc.

Completed

A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia (RALLY)

Fibromyalgia

United States
Gamaleya Research Institute of Epidemiology and...

Not yet recruiting

Clinical Trial to Study the Efficacy and Safety of Fluorothiazinone (N.F. Gamaleya NRCEM) in Prophylaxis of Nosocomial Bacterial Infections With Participation of Patients on MV

Gram-Negative Bacterial Infections | Bacteremia Caused by Gram-Negative Bacteria | Gram Negative Pneumonia
Tonix Pharmaceuticals, Inc.

Completed

A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia (RELIEF)

Fibromyalgia

United States
Tonix Pharmaceuticals, Inc.

Completed

A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia (AFFIRM)

Nervous System Diseases | Musculoskeletal Diseases | Rheumatic Diseases | Muscular Diseases | Neuromuscular Diseases | Fibromyalgia | Myofascial Pain Syndromes

United States
McGill University Health Centre/Research Institute...
Centre de Recherche du Centre Hospitalier de l'Université de Montréal; CIHR... and other collaborators

Terminated

Cannabinoids in PLWHIV on Effective ART

HIV Infections

Canada
Viriom

Not yet recruiting

Study Evaluating the Efficacy and Safety of AV5080 in Patients With Uncomplicated Influenza

Influenza

Russian Federation
Protalex, Inc.

Completed

Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis (SPARTA)

Arthritis, Rheumatoid

United States
Novo Nordisk A/S

Terminated

A Research Study Looking Into Levels of the Medicine NNC0385-0434 in the Body and How Well it is Tolerated in Participants With Impaired Kidney Function Compared to Participants With Normal Kidney Function

Chronic Kidney Disease

Germany
University of California, San Diego

Not yet recruiting

Use of Stable Carbon And Nitrogen Isotopes to Improve Dietary Assessment for Cardiovascular Disease (I-CAN)

Healthy Adults

United States
Tonix Pharmaceuticals, Inc.
Premier Research Group plc

Terminated

Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD (HONOR)

PTSD

United States
Tonix Pharmaceuticals, Inc.

Completed

Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions (P202)

PTSD

United States
Santen Inc.

Completed

A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration (PAVE)

Age-Related Macular Degeneration

United States
Chiesi Farmaceutici S.p.A.
ICON plc

Recruiting

Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease (RISE)

Fabry Disease

Japan
Bristol-Myers Squibb

Completed

Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects (INH-189-006)

Hepatitis C

United States, Puerto Rico
Tonix Pharmaceuticals, Inc.

Completed

Dose-Proportionality and Food Effect Study of TNX-102 SL

Healthy Subjects

Canada
Tonix Pharmaceuticals, Inc.

Completed

12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients (BESTFIT-OLE)

Primary Fibromyalgia

United States
Tonix Pharmaceuticals, Inc.
Premier Research Group plc

Terminated

12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients

PTSD

United States
Zalicus

Terminated

CRx-102 Osteoarthritis Multicenter Evaluation Trial (COMET-1)

Knee Osteoarthritis

United States, Canada
Chinese PLA General Hospital

Completed

Low Dose Ruxolitinib in Combination With Methylprednisolone

Stem Cell Transplant Complications | aGVHD

China
University of Michigan

Completed

Study of the Safety of KSP Heptapeptide (KSP-910638G)

Healthy Adults

United States
Ottawa Heart Institute Research Corporation
Heart and Stroke Foundation of Ontario

Completed

Endothelial Modulation for Angiogenic Therapy

Coronary Artery Disease

Canada
Merck Sharp & Dohme LLC

Completed

MK3207 for Treatment of Acute Migraines (3207-005)

Migraine
Chiesi Farmaceutici S.p.A.
ICON plc

Not yet recruiting

A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease (FLY)

Fabry Disease
Tonix Pharmaceuticals, Inc.

Withdrawn

Safety and Efficacy Study of TNX-102 SL in Participants With PTSD

PTSD

Kenya
Bayer

Completed

Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies

Neoplasm

United States
Virginia Commonwealth University
GlaxoSmithKline; Puma Biotechnology, Inc.

Recruiting

Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer (iNNOVATE)

Ovarian Cancer | Advanced Solid Tumor

United States
Genzyme, a Sanofi Company

Terminated

ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial (ZACFAST)

Breast Cancer

Italy
Tonix Pharmaceuticals, Inc.

Completed

Steady-State Pharmacokinetic Comparison Study of TNX-102 SL 5.6 mg Versus AMRIX® 30 mg ER Capsules

Healthy Subjects

Canada
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects

Cardiovascular Disease | Healthy Male Subjects

United Kingdom
Novo Nordisk A/S

Completed

A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease

Atherosclerotic Cardiovascular Disease

Germany, Poland, United States, Netherlands, Japan, Greece, Belgium
Midnight Pharma, LLC

Completed

Almorexant (ACT-078573) in Elderly Subjects With Chronic Primary Insomnia

Chronic Primary Insomnia

United States
Tonix Pharmaceuticals, Inc.

Completed

BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT) (BESTFIT)

Primary Fibromyalgia

United States

3

Subscribe